GTBP Common Stock vs Net Debt Analysis

GTBP Stock

USD 3.52 0.05 1.40%

GT Biopharma financial indicator trend analysis is much more than just examining GT Biopharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GT Biopharma is a good investment. Please check the relationship between GT Biopharma Common Stock and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.

Common Stock vs Net Debt

Common Stock vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GT Biopharma Common Stock account and Net Debt. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between GT Biopharma's Common Stock and Net Debt is -0.41. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Net Debt in the same time period over historical financial statements of GT Biopharma, assuming nothing else is changed. The correlation between historical values of GT Biopharma's Common Stock and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of GT Biopharma are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Common Stock i.e., GT Biopharma's Common Stock and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.41

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from GT Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GT Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.At this time, GT Biopharma's Selling General Administrative is relatively stable compared to the past year. As of 06/05/2024, Issuance Of Capital Stock is likely to grow to about 10.2 M, while Sales General And Administrative To Revenue is likely to drop 2.17.

	2023	2024 (projected)
Total Operating Expenses	13.6M	10.7M
Cost Of Revenue	3.6K	3.4K

Total Operating Expenses Cost Of Revenue

GT Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Non Current Liabilities Total	Short Long Term Debt Total	Short Term Debt	Other Assets	Preferred Stock Total Equity
Total Assets		-0.14	-0.22	0.97	-0.15	-0.21	-0.03	0.15	-0.01	0.99	-0.06	-0.02	-0.16	-0.06	-0.07	-0.18	0.26	-0.22	-0.15	-0.03	-0.13	-0.1	-0.23	-0.22	-0.11	-0.31
Other Current Liab	-0.14		0.83	-0.32	-0.15	0.22	0.19	-0.22	-0.21	-0.11	-0.14	-0.19	-0.16	-0.13	-0.09	-0.21	-0.26	0.83	-0.15	-0.19	-0.19	-0.1	0.15	0.13	-0.12	-0.23
Total Current Liabilities	-0.22	0.83		-0.43	-0.29	0.64	-0.01	-0.14	-0.03	-0.19	-0.24	-0.18	-0.34	-0.26	-0.2	0.22	-0.1	1.0	-0.29	-0.18	-0.34	0.39	0.66	0.64	-0.25	-0.04
Total Stockholder Equity	0.97	-0.32	-0.43		-0.07	-0.34	-0.03	0.17	0.0	0.96	0.0	0.02	-0.07	0.0	-0.02	-0.22	0.27	-0.43	-0.07	0.01	-0.05	-0.18	-0.36	-0.35	-0.04	-0.28
Property Plant And Equipment Net	-0.15	-0.15	-0.29	-0.07		-0.25	-0.16	-0.1	0.15	-0.16	0.71	0.1	0.56	0.69	0.69	0.13	0.14	-0.29	1.0	0.12	0.46	-0.09	-0.19	-0.19	0.67	0.64
Net Debt	-0.21	0.22	0.64	-0.34	-0.25		0.04	-0.43	-0.32	-0.12	-0.19	-0.57	-0.24	-0.21	-0.17	0.38	-0.12	0.63	-0.25	-0.58	-0.41	0.59	0.94	0.94	-0.2	0.03
Retained Earnings	-0.03	0.19	-0.01	-0.03	-0.16	0.04		-0.73	-0.56	0.07	0.27	-0.69	0.52	0.28	0.3	-0.55	-0.97	-0.01	-0.16	-0.68	0.37	-0.41	-0.15	-0.16	0.37	-0.54
Accounts Payable	0.15	-0.22	-0.14	0.17	-0.1	-0.43	-0.73		0.71	0.02	-0.23	0.93	-0.41	-0.24	-0.25	0.33	0.75	-0.14	-0.1	0.93	-0.07	0.16	-0.21	-0.2	-0.3	0.27
Cash	-0.01	-0.21	-0.03	0.0	0.15	-0.32	-0.56	0.71		-0.13	0.07	0.83	-0.08	0.05	0.06	0.56	0.52	-0.03	0.15	0.84	0.24	0.43	0.03	0.03	0.02	0.55
Non Current Assets Total	0.99	-0.11	-0.19	0.96	-0.16	-0.12	0.07	0.02	-0.13		-0.05	-0.17	-0.13	-0.06	-0.06	-0.23	0.17	-0.19	-0.16	-0.17	-0.15	-0.11	-0.18	-0.17	-0.09	-0.37
Non Currrent Assets Other	-0.06	-0.14	-0.24	0.0	0.71	-0.19	0.27	-0.23	0.07	-0.05		-0.07	0.92	1.0	0.99	0.1	-0.26	-0.24	0.71	-0.04	0.86	-0.09	-0.14	-0.14	0.99	0.49
Cash And Short Term Investments	-0.02	-0.19	-0.18	0.02	0.1	-0.57	-0.69	0.93	0.83	-0.17	-0.07		-0.22	-0.07	-0.09	0.32	0.67	-0.18	0.1	1.0	0.11	0.1	-0.31	-0.3	-0.12	0.4
Common Stock Total Equity	-0.16	-0.16	-0.34	-0.07	0.56	-0.24	0.52	-0.41	-0.08	-0.13	0.92	-0.22		0.92	0.92	-0.06	-0.52	-0.34	0.56	-0.19	0.9	-0.2	-0.25	-0.26	0.96	0.28
Common Stock Shares Outstanding	-0.06	-0.13	-0.26	0.0	0.69	-0.21	0.28	-0.24	0.05	-0.06	1.0	-0.07	0.92		0.99	0.04	-0.27	-0.26	0.69	-0.05	0.86	-0.15	-0.17	-0.18	0.99	0.47
Inventory	-0.07	-0.09	-0.2	-0.02	0.69	-0.17	0.3	-0.25	0.06	-0.06	0.99	-0.09	0.92	0.99		0.08	-0.29	-0.2	0.69	-0.06	0.86	-0.1	-0.12	-0.13	0.98	0.46
Other Current Assets	-0.18	-0.21	0.22	-0.22	0.13	0.38	-0.55	0.33	0.56	-0.23	0.1	0.32	-0.06	0.04	0.08		0.46	0.22	0.13	0.33	0.07	0.94	0.61	0.61	0.04	0.64
Other Stockholder Equity	0.26	-0.26	-0.1	0.27	0.14	-0.12	-0.97	0.75	0.52	0.17	-0.26	0.67	-0.52	-0.27	-0.29	0.46		-0.1	0.14	0.66	-0.38	0.33	0.04	0.06	-0.36	0.43
Total Liab	-0.22	0.83	1.0	-0.43	-0.29	0.63	-0.01	-0.14	-0.03	-0.19	-0.24	-0.18	-0.34	-0.26	-0.2	0.22	-0.1		-0.29	-0.18	-0.34	0.38	0.65	0.64	-0.25	-0.04
Property Plant And Equipment Gross	-0.15	-0.15	-0.29	-0.07	1.0	-0.25	-0.16	-0.1	0.15	-0.16	0.71	0.1	0.56	0.69	0.69	0.13	0.14	-0.29		0.12	0.46	-0.09	-0.19	-0.19	0.67	0.64
Total Current Assets	-0.03	-0.19	-0.18	0.01	0.12	-0.58	-0.68	0.93	0.84	-0.17	-0.04	1.0	-0.19	-0.05	-0.06	0.33	0.66	-0.18	0.12		0.13	0.11	-0.31	-0.3	-0.09	0.42
Common Stock	-0.13	-0.19	-0.34	-0.05	0.46	-0.41	0.37	-0.07	0.24	-0.15	0.86	0.11	0.9	0.86	0.86	0.07	-0.38	-0.34	0.46	0.13		-0.12	-0.31	-0.31	0.88	0.38
Non Current Liabilities Total	-0.1	-0.1	0.39	-0.18	-0.09	0.59	-0.41	0.16	0.43	-0.11	-0.09	0.1	-0.2	-0.15	-0.1	0.94	0.33	0.38	-0.09	0.11	-0.12		0.78	0.78	-0.13	0.42
Short Long Term Debt Total	-0.23	0.15	0.66	-0.36	-0.19	0.94	-0.15	-0.21	0.03	-0.18	-0.14	-0.31	-0.25	-0.17	-0.12	0.61	0.04	0.65	-0.19	-0.31	-0.31	0.78		1.0	-0.17	0.25
Short Term Debt	-0.22	0.13	0.64	-0.35	-0.19	0.94	-0.16	-0.2	0.03	-0.17	-0.14	-0.3	-0.26	-0.18	-0.13	0.61	0.06	0.64	-0.19	-0.3	-0.31	0.78	1.0		-0.18	0.25
Other Assets	-0.11	-0.12	-0.25	-0.04	0.67	-0.2	0.37	-0.3	0.02	-0.09	0.99	-0.12	0.96	0.99	0.98	0.04	-0.36	-0.25	0.67	-0.09	0.88	-0.13	-0.17	-0.18		0.42
Preferred Stock Total Equity	-0.31	-0.23	-0.04	-0.28	0.64	0.03	-0.54	0.27	0.55	-0.37	0.49	0.4	0.28	0.47	0.46	0.64	0.43	-0.04	0.64	0.42	0.38	0.42	0.25	0.25	0.42

Click cells to compare fundamentals

GT Biopharma Account Relationship Matchups

GT Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	396K	5.7M	32.2M	16.7M	14.1M	13.2M
Other Current Liab	4.4M	383K	138K	1.7M	2.2M	2.3M
Total Current Liabilities	19.7M	35.1M	10.3M	4.9M	6.6M	6.9M
Total Stockholder Equity	(19.1M)	(29.3M)	21.9M	11.7M	7.5M	7.1M
Property Plant And Equipment Net	35K	110K	0.0	165K	53K	50.4K
Net Debt	13.3M	21.0M	(8.9M)	(5.5M)	(1.0M)	(970.0K)
Retained Earnings	(567.3M)	(595.6M)	(653.6M)	(674.5M)	(682.1M)	(648.0M)
Accounts Payable	1.9M	2.2M	8.2M	3.1M	4.3M	4.5M
Cash	28K	5.3M	9.0M	5.7M	1.1M	1.2M
Non Current Assets Total	25.3M	122K	0.0	174K	53K	50.4K
Cash And Short Term Investments	28K	5.3M	32.0M	16.5M	14.0M	14.7M
Common Stock Total Equity	50K	51K	70K	52K	46.8K	44.5K
Common Stock Shares Outstanding	112.8K	146.2K	938.5K	1.1M	1.3M	1.3M
Liabilities And Stockholders Equity	396K	5.7M	32.2M	16.7M	14.1M	13.2M
Other Current Assets	246K	364K	190K	54K	84K	79.8K
Other Stockholder Equity	548.1M	566.3M	673.2M	686.2M	689.5M	724.0M
Total Liab	19.7M	35.1M	10.3M	5.0M	6.6M	7.1M
Property Plant And Equipment Gross	35K	110K	0.0	165K	53K	50.4K
Total Current Assets	274K	5.7M	32.2M	16.6M	14.1M	14.8M
Common Stock	70K	52K	1.1M	33K	1K	950.0
Short Long Term Debt Total	10.8M	13.4M	26.3M	174K	58K	55.1K
Short Term Debt	10.8M	13.4M	26.3M	110K	58K	55.1K
Net Tangible Assets	(13.7M)	(19.1M)	(29.3M)	21.9M	25.2M	26.5M
Short Long Term Debt	31K	10.8M	13.2M	26.3M	35.7K	33.9K
Net Invested Capital	(5.9M)	(2.9M)	21.9M	11.7M	7.5M	7.1M
Net Working Capital	(19.4M)	(29.4M)	21.9M	11.6M	7.4M	7.8M
Capital Stock	73K	55K	1.1M	34K	2K	1.9K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for GTBP Stock Analysis

When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GTBP Common Stock vs Net Debt Analysis

Common Stock vs Net Debt

Common Stock vs Net Debt Correlation Analysis

Correlation Coefficient

Common Stock

Net Debt

GT Biopharma fundamental ratios Correlations

GT Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GT Biopharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Additional Tools for GTBP Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock Shares Outstanding	+ 1.0	Non Currrent Assets Other
Total Current Assets	+ 1.0	Cash And Short Term Investments
Short Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 0.99	Total Assets

Other Stockholder Equity	- 0.97	Retained Earnings
Accounts Payable	- 0.73	Retained Earnings
Cash And Short Term Investments	- 0.69	Retained Earnings
Total Current Assets	- 0.68	Retained Earnings
Total Current Assets	- 0.58	Net Debt
Cash And Short Term Investments	- 0.57	Net Debt